Brasília – Leandro Safatle, the newly appointed director-president of Anvisa, has pledged to tackle the backlog of drug registrations and streamline regulatory review as one of his top priorities.

During the IV Brazilian Health Innovation Summit, Safatle emphasized that resolving the agency’s registration queues will be his first focus, followed by measures to strengthen innovation. According to him, Anvisa must act as a facilitator of technological development in the country.

Long approval times have long been a major complaint from pharmaceutical companies. Delays in both new registrations and post-approval changes are seen as barriers to market entry and innovation in Brazil.

Safatle takes office at a time when the agency faces the dual challenge of ensuring rigorous regulatory standards while responding more quickly to industry needs. His statements align with commitments already made by other Anvisa directors to accelerate drug registration without compromising safety and efficacy.

Source: Panorama Farmacêutico

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com